NEA Partners 15, L.P. has an estimated net worth of $2.5 Billion. This is based on reported shares across multiple companies, which include Nightstar Therapeutics plc, Berkshire Grey, Inc., Reneo Pharmaceuticals, Inc., Arcellx, Inc., IonQ, Inc., Senti Biosciences, Inc., Cascadian Therapeutics, Inc., Robinhood Markets, Inc., Nkarta, Inc., NeueHealth, Inc., AVEO PHARMACEUTICALS, INC., Desktop Metal, Inc., Inozyme Pharma, Inc., Millendo Therapeutics, Inc., Eargo, Inc., Annexon, Inc., ARCA biopharma, Inc., and Achaogen Inc.

2018 was NEA Partners 15, L.P.'s most active year for acquiring shares with 26 total transactions. NEA Partners 15, L.P.'s most active month to acquire stocks was the month of September. 2021 was NEA Partners 15, L.P.'s most active year for disposing of shares, totalling 24 transactions. NEA Partners 15, L.P.'s most active month to dispose stocks was the month of September. 2021 saw NEA Partners 15, L.P. paying a total of $87,118,710.00 for 208,503,857 shares, this is the most they've acquired in one year. In 2019 NEA Partners 15, L.P. cashed out on 6,662,532 shares for a total of $169,894,566.00, their largest year based on trade value.